Nonalcoholic steatohepatitis (NASH) is within the spectrum of nonalcoholic fatty liver
disease (NAFLD) and can progress to fibrosis, cirrhosis, and even hepatocellular carcinoma …

Nonalcoholic fatty liver disease (NAFLD) has become the most prevalent cause of liver
disease, increasingly contributing to the burden of liver transplantation. In search for …

Nonalcoholic fatty liver disease (NAFLD) is a highly prevalent chronic liver condition
evolving in a proportion of patients into nonalcoholic steatohepatitis (NASH), an aggressive …

Non‐alcoholic fatty liver disease (NAFLD) is currently evolving as the most common liver
disease worldwide. It may progress to liver cirrhosis and liver cancer and is poised to …

The farnesoid X receptor (FXR) is a nuclear receptor and transcriptional regulator activated
by bile acids or synthetic FXR agonists. FXR is expressed highly in the liver and intestine …

Non-alcoholic fatty liver disease (NAFLD) is a complex disease, affecting not just the liver,
but also all other organs in the body. Despite an increasing amount of people worldwide …

The farnesoid X receptor (FXR), a bile acid (BA)-activated nuclear receptor highly expressed
in liver and intestine, regulates the expression of genes involved in cholesterol and bile acid …

The prevalence of nonalcoholic fatty liver disease (NAFLD) worldwide has increased at an
alarming rate, which will likely result in enormous medical and economic burden. NAFLD …

Non-alcoholic steatohepatitis (NASH) is a progressive, chronic, liver disease whose
prevalence is growing worldwide. Despite several agents being under development for …

Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease, affecting
approximately 20%-30% of the population in Western countries. Nonalcoholic …